{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:56:46Z","timestamp":1768557406407,"version":"3.49.0"},"reference-count":25,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Purpose: With the addition of palbociclib to endocrine therapy, many hormone receptor-positive (HR+) metastatic breast cancer (mBC) patients experience toxicities that can lead to dose reductions and cycle delays. We examined the actual doses of palbociclib received by patients and their treatment responses. These dose adjustments, made at the physician\u2019s discretion, are not always consistent with pharmaceutical company recommendations. The aim of this study was to assess the influence of dose adjustments on dose intensity and treatment response in our patients. Methods: Records of patients with HR+ mBC treated with palbociclib between December 2016 and January 2019 at the Sainte-Catherine Institute were retrospectively reviewed. Dose intensity was defined as the total dose of palbociclib received by each patient during the first six months of treatment. Anticipated dose reductions and extended cycle delays were recorded. Treatment response at six months and survival were assessed using statistical analyses. Results: A total of 131 women were included; the median age was 67 years. Forty-six patients (35%) experienced an anticipated dose reduction or an extended cycle delay during the first six months of treatment. Logistic regression analysis showed that factors correlated with six-month treatment response included anticipated dose reduction or extended cycle delay (OR = 14.6, 95% CI 3.74\u201397.4, p &lt; 0.001), cycle delay &gt; 4 weeks (OR = 5.94, 95% CI 1.58\u201321, p = 0.01), initial dosage &lt; 125 mg (OR = 4.09, 95% CI 1.13\u201313.7, p = 0.034), and six-month dose intensity &lt; 14,250 mg (OR = 26.0, 95% CI 4.91\u2013481, p &lt; 0.001). Conclusions: In this real-world assessment of clinical outcomes in French patients with HR+ mBC treated with palbociclib, a palbociclib dose intensity lower than recommended\u2014particularly due to cycle delays longer than four weeks\u2014was associated with an increased risk of six-month disease progression.<\/jats:p>","DOI":"10.3390\/curroncol33010051","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:35:38Z","timestamp":1768487738000},"page":"51","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Palbociclib in Combination with Endocrine Therapy in Patients with Metastatic Breast Cancer in a Real-World Population: Impact of Dose-Intensity, Dose Reductions and Cycle Delays on Efficacy"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7072-5860","authenticated-orcid":false,"given":"Julie","family":"Coussirou","sequence":"first","affiliation":[{"name":"Sainte Catherine, Institut du Cancer Avignon-Provence, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Grenier","sequence":"additional","affiliation":[{"name":"Sainte Catherine, Institut du Cancer Avignon-Provence, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Mege","sequence":"additional","affiliation":[{"name":"Sainte Catherine, Institut du Cancer Avignon-Provence, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Arnaud","sequence":"additional","affiliation":[{"name":"Sainte Catherine, Institut du Cancer Avignon-Provence, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"De Crozals","sequence":"additional","affiliation":[{"name":"Sainte Catherine, Institut du Cancer Avignon-Provence, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Bonnet","sequence":"additional","affiliation":[{"name":"Clinique Beausoleil, 34080 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9a","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Sainte Catherine, Institut du Cancer Avignon-Provence, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"ref_1","unstructured":"(2025, August 07). World Health Organization: Global Cancer Data. Available online: https:\/\/gco.iarc.fr\/."},{"key":"ref_2","unstructured":"(2025, August 07). INCA\u2014Les Cancers en France. Available online: https:\/\/www.e-cancer.fr\/ressources\/cancers_en_france\/."},{"key":"ref_3","unstructured":"NCCN (2019, June 19). Clinical Practice Guidelines in Oncology (NC; Breast Cancer Version 1.2019 March 14, 2019). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdw544","article-title":"3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13058-015-0542-y","article-title":"Mechanisms of endocrine resistance in breast cancer: An overview of the proposed roles of noncoding RNA","volume":"17","author":"Hayes","year":"2015","journal-title":"Breast Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","article-title":"Palbociclib in Combination with Fulvestrant in Women with Hormone Receptor-Positive\/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis from a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)","volume":"21","author":"Verma","year":"2016","journal-title":"Oncologist"},{"key":"ref_7","unstructured":"FDA (2019, June 19). Palbociclib Full Prescribing Informations, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207103s000lbl.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s10147-018-1353-9","article-title":"Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients","volume":"24","author":"Mukai","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-020-00771-5","article-title":"Impact of dose reduction on efficacy: Implications of exposure-response analysis of Palbociclib","volume":"16","author":"Zheng","year":"2021","journal-title":"Target. Oncol."},{"key":"ref_10","unstructured":"CTCAE (2019, June 19). Version 4.03: June 14, 2010. Available online: https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): A randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1634\/theoncologist.2017-0072","article-title":"Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results","volume":"22","author":"Loibl","year":"2017","journal-title":"Oncologist"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2018.05.017","article-title":"Palbociclib plus endocrine therapy in older women with HR+\/HER2\u2212 advanced breast cancer: A pooled analysis of randomised PALOMA clinical studies","volume":"101","author":"Rugo","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clbc.2019.06.010","article-title":"Progression-Free Survival for real-world use of Palbociclib in Hormone Receptor-Positive Metastatic Breast cancer","volume":"20","author":"Wilkie","year":"2019","journal-title":"Clin. Breast Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s11096-020-01193-z","article-title":"Real-world experience of palbociclib and ribociclib: Novel oral therapy in metastatic breast cancer","volume":"43","author":"Cabetas","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.breast.2018.10.009","article-title":"Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+\/HER2-negative advanced\/metastatic breast cancer in real-world settings in the US: Results from the IRIS study","volume":"43","author":"Mitra","year":"2019","journal-title":"Breast"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10549-019-05181-4","article-title":"Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population","volume":"175","author":"Clifton","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1758835920987651","DOI":"10.1177\/1758835920987651","article-title":"Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive\/HER2 receptor-negative metastatic breast cancer: A real-world multicentre Italian study","volume":"13","author":"Palumbo","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-019-05176-1","article-title":"Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy","volume":"176","author":"Varella","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13058-021-01409-8","article-title":"Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+\/HER2\u2212 metastatic breast cancer in US real-world clinical practice","volume":"23","author":"DeMichele","year":"2021","journal-title":"Breast Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.breast.2021.11.013","article-title":"Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer","volume":"60","author":"Ismail","year":"2021","journal-title":"Breast"},{"key":"ref_25","first-page":"290","article-title":"Palbociclib Associated with Endocrine Therapy in Patients with Metastatic Breast Cancer: Predictive Factors of Severe Early Hematological Toxicity","volume":"11","author":"Vazquez","year":"2019","journal-title":"J. Cancer Sci. Ther."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/51\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T15:19:31Z","timestamp":1768490371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/51"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["curroncol33010051"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33010051","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]}}}